Dare Bioscience (DARE) Common Equity (2013 - 2026)
Dare Bioscience's (DARE) quarterly Common Equity came in at $2.8 million in Q4 2025, up 147.28% YoY from $1.1 million in Q4 2024, and down 0.53% on a QoQ basis from $2.9 million in Q3 2025.
Dare Bioscience (DARE) Common Equity (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Common Equity data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Common Equity rose 147.28% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 147.28% YoY) and the FY2025 annual result came in at $2.8 million, up 147.28% from the prior year.
- Common Equity declined to $2.8 million in Q4 2025, from $2.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $38.8 million in Q4 2021 to a low of -$12.7 million in Q2 2025.
- A 5-year average of $7.3 million and a median of $2.9 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity jumped 3464.87% — and 2025, when it tumbled 576.63%.
- Tracing DARE's Common Equity over 5 years: stood at $38.8 million in 2021, then slumped by 71.33% to $11.1 million in 2022, then plunged by 145.42% to -$5.0 million in 2023, then fell by 19.11% to -$6.0 million in 2024, then jumped by 147.28% to $2.8 million in 2025.
- The last three Common Equity figures came in at $2.8 million (Q4 2025), $2.9 million (Q3 2025), and -$12.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | -560,100.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -560,100.00 |
| Dec 31, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Jun 30, 2025 | -12.73 Mn |
| Mar 31, 2025 | -9.56 Mn |
| Dec 31, 2024 | -6.01 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | 2.67 Mn |
| Mar 31, 2024 | -11.00 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Sep 30, 2023 | -2.29 Mn |
| Jun 30, 2023 | -2.72 Mn |
| Mar 31, 2023 | 4.97 Mn |
| Dec 31, 2022 | 11.11 Mn |
| Sep 30, 2022 | 26.34 Mn |
| Jun 30, 2022 | 33.03 Mn |
| Mar 31, 2022 | 30.88 Mn |
| Dec 31, 2021 | 38.75 Mn |
| Sep 30, 2021 | 31.89 Mn |
| Jun 30, 2021 | 7.74 Mn |